Vanguard Group Inc Gain Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 145,217 shares of GANX stock, worth $312,216. This represents 0.0% of its overall portfolio holdings.
Number of Shares
145,217
Previous 145,217
-0.0%
Holding current value
$312,216
Previous $185,000
39.46%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding GANX
# of Institutions
24Shares Held
2.4MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.27 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.22 Million0.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$719,3720.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$584,7390.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$264,4500.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $25.5M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...